James Ballenger to Double-Blind Method
This is a "connection" page, showing publications James Ballenger has written about Double-Blind Method.
Connection Strength
0.260
-
Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
Score: 0.030
-
Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan; 155(1):36-42.
Score: 0.027
-
Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S.
Score: 0.025
-
Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72.
Score: 0.020
-
Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
Score: 0.019
-
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol. 1992; 47:431-47.
Score: 0.018
-
Effect of alprazolam on depression in panic disorder. J Clin Psychopharmacol. 1991 Apr; 11(2):145-6.
Score: 0.017
-
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991; 27(2):171-9.
Score: 0.017
-
Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70.
Score: 0.015
-
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22.
Score: 0.014
-
A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
Score: 0.006
-
Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
Score: 0.006
-
A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995 Apr 01; 37(7):462-6.
Score: 0.006
-
Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord. 1994 Jan; 30(1):5-13.
Score: 0.005
-
Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry. 1992 Nov; 149(11):1556-62.
Score: 0.005
-
Discontinuation of alprazolam after long-term treatment of panic-related disorders. J Clin Psychopharmacol. 1992 Oct; 12(5):352-4.
Score: 0.005
-
A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992 Apr; 12(2):96-103.
Score: 0.005
-
Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Aug 01; 30(3):225-32.
Score: 0.004
-
Sequence of improvement in agoraphobia with panic attacks. J Psychiatr Res. 1990; 24(1):1-8.
Score: 0.004
-
Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989 May; 146(5):617-21.
Score: 0.004
-
Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry. 1983 Dec; 140(12):1602-4.
Score: 0.003
-
Biochemical effects of carbamazepine: relationship to its mechanisms of action in affective illness. Prog Neuropsychopharmacol Biol Psychiatry. 1983; 7(2-3):263-71.
Score: 0.002
-
Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry. 1982 Sep; 17(9):1037-45.
Score: 0.002
-
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan; 37(1):51-9.
Score: 0.002